CVRx (CVRX) Q4 2025 earnings review
Growth Stalls in Q4; 2026 Hopes Pinned on Reimbursement Wins
CVRx ended 2025 with a significant deceleration, posting only 4% YoY revenue growth in Q4 compared to double-digits earlier in the year. The promised sales force productivity ramp has yet to fully materialize in the numbers, with active center additions slowing to a crawl (only +2 QoQ). However, the thesis remains alive due to a major regulatory win: effective Jan 1, 2026, Barostim has Category I CPT codes, removing the 'experimental' label that caused automatic insurance denials. Management guides for a re-acceleration to mid-teens growth in 2026, but with cash burn continuing and debt rising, execution is critical.
🐂 Bull Case
The implementation of Category I CPT codes on Jan 1, 2026, is a structural game-changer. It eliminates automatic 'experimental' denials for prior authorizations, which should shorten the sales cycle and improve physician payment consistency.
Despite soft top-line growth, gross margins expanded to 86% (up from 83% last year) due to higher average selling prices and manufacturing efficiencies. This demonstrates strong unit economics if volume ever scales.
🐻 Bear Case
After a massive sales force overhaul in early 2025, the 'ramp' is taking longer than expected. Q4 revenue grew only 4%, and active implanting centers barely moved (+2 vs Q3). The narrative of a 'more productive' sales team contradicts the current data.
CVRx burned ~$40M in operating/investing cash in FY25, ending with $75.7M on hand. While they secured more debt capacity (drawing $10M immediately), adding leverage with a ~9.4%+ interest rate while unprofitable increases financial risk.
⚖️ Verdict: ⚪
Neutral. The deceleration to 4% growth is a major concern for a small-cap growth stock. While the reimbursement catalyst for 2026 is real and significant, the company has yet to prove its new sales team can actually drive volume. Investors should wait for evidence of the promised re-acceleration in Q1 2026.
Key Themes
Growth Deceleration to Low Single Digits
Revenue momentum has evaporated. Growth slowed from 15% in H1 2025 to 10% in Q3, and now effectively stalled at 4% in Q4. This contradicts the narrative of building momentum. While management points to Q1 2026 guidance as a rebound, the current trend is indisputably negative.
Category I CPT Code Implementation
This is the primary bull argument. As of Jan 1, 2026, Barostim procedures use permanent CPT codes. Previously, 'Category III' (temporary) codes allowed insurers to auto-deny claims as experimental. Removing this administrative hurdle should theoretically grease the wheels for faster adoption, though management has previously warned this is not an overnight 'light switch' event.
Stagnant Center Growth
Active implanting centers—a key leading indicator—are plateauing. The company added only 2 net active centers in Q4 (252 vs 250 in Q3). Earlier in the year, they were adding 10-13 per quarter. Without expanding the base of prescribing hospitals, growth relies entirely on deepening utilization in existing accounts, which has proven difficult.
BENEFIT-HF Clinical Trial Launch
CVRx initiated the BENEFIT-HF trial, with enrollment starting Q2 2026. This trial targets heart failure patients with higher ejection fractions (up to 50%). Success here would triple the Total Addressable Market (TAM). While positive long-term, it adds near-term cost ($20-30M over 5-7 years) without immediate revenue benefit.
Rising Expenses
Despite the revenue slowdown, costs are rising. SG&A increased 9% YoY in Q4 to $22M, driven by headcount. With the new clinical trial starting, R&D/OpEx will remain elevated (guided $103-107M for FY26). The path to breakeven remains distant.
Other KPIs
Accelerating. Up from 83% a year ago. Driven by Average Selling Price (ASP) increases and manufacturing efficiencies. This is an elite margin profile for a device company, providing significant operating leverage potential if sales volume ever recovers.
Decelerating. Down from $105.9M at end of 2024. The company amended its debt facility to access $100M total capital, immediately drawing $10M. This extends the runway but increases the debt burden on a loss-making entity.
Stable/Decelerating. +4% YoY. This is the core business. The slowdown here is the primary concern, as international revenue remains a small fraction of the total ($1.1M).
Guidance
Accelerating. The midpoint implies ~14.5% YoY growth, a significant improvement from the 4% seen in Q4 2025. Management is banking on the CPT code change and sales force maturity to drive this rebound.
Accelerating. Midpoint implies ~15% YoY growth. Note that 25Q1 was a particularly weak quarter (easy comparison), which helps the growth optic. Sequential growth from 25Q4 ($16M) to 26Q1 ($14.2M mid) is expected to be negative due to typical seasonality.
Increasing. Up from $99.6M in FY25. Indicates continued heavy investment in sales and the new BENEFIT-HF trial ($20-30M total cost over several years) despite the current cash burn.
Key Questions
Active Center Stagnation
Net active centers increased by only 2 in Q4 (252 vs 250). Is this a saturation issue, or a deliberate pause in opening new accounts to focus on depth? If the latter, why is revenue growth only 4%?
Q1 2026 Sequential Drop
Guidance suggests a steep sequential drop from Q4 ($16M) to Q1 ($14.2M midpoint). Is this purely patient deductibles seasonality, or is there disruption expected from hospitals updating their billing systems for the new CPT codes?
Cash Runway
With ~$76M in cash and a burn rate of ~$40M+, plus rising debt service costs, does the current plan require additional equity financing before the BENEFIT-HF trial concludes?